Cargando…

Incretin Mimetics: Promising New Therapeutic Options in the Treatment of Type 2 Diabetes

OBJECTIVES: To review the current state of diabetes treatment from a clinical and management perspective and explore the role that new biologic pharmaceuticals may offer patients who fail to meet or maintain glycemic goals with existing treatment options. SUMMARY: Key clinical areas involve the role...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gleeson, Jeremy M., Berenbeim, David M., Gilkin, Robert J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Academy of Managed Care Pharmacy 2005
Materias:	Supplement
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10437539/ https://www.ncbi.nlm.nih.gov/pubmed/16137221 http://dx.doi.org/10.18553/jmcp.2005.11.s7.1

Ejemplares similares

Incretin mimetics: a novel therapeutic option for patients with type 2 diabetes – a review
por: Hansen, Katrine B, et al.
Publicado: (2010)

What Are Incretins, and How Will They Influence the Management of Type 2 Diabetes?
por: Bonde, Lawrence, et al.
Publicado: (2006)

The Changing Landscape of Type 2 Diabetes: The Role of Incretin-Based Therapies in Managed Care Outcomes
por: Triplitt, Curtis, et al.
Publicado: (2007)

Metabolic Effects of the Incretin Mimetic Exenatide in the Treatment of Type 2 Diabetes
por: Schnabel, Catherine A, et al.
Publicado: (2006)

The Influence of Incretin Mimetics on Cardiovascular Risk Factors in Diabetes
por: Kinalska, Ida, et al.
Publicado: (2012)

Therapeutic Options in the Prevention and Treatment of Postmenopausal Osteoporosis
por: Kamel, Hosam K., et al.
Publicado: (2006)

Asthma Management Guidelines: Updates, Advances, and New Options
por: Navarro, Robert P., et al.
Publicado: (2007)

Incretins as a Potential Treatment Option for Gestational Diabetes Mellitus
por: Pilszyk, Aleksandra, et al.
Publicado: (2022)

Incretin-based therapy: a powerful and promising weapon in the treatment of type 2 diabetes mellitus
por: Koliaki, Chrysi, et al.
Publicado: (2011)

Managing Patients With Chronic Angina: Emerging Therapeutic Options for Improving Clinical Efficacy and Outcomes
por: Dobesh, Paul P., et al.
Publicado: (2006)

Incretin-based therapies: new treatments for type 2 diabetes in the new millennium
por: Khoo, Joan, et al.
Publicado: (2009)

Incretin Hormones and Type 2 Diabetes—Mechanistic Insights and Therapeutic Approaches
por: Boer, Geke Aline, et al.
Publicado: (2020)

New prospects for incretin‐related drugs in the treatment of type 2 diabetes
por: Kimura, Tomohiko, et al.
Publicado: (2020)

Incretin hormones and type 2 diabetes
por: Nauck, Michael A., et al.
Publicado: (2023)

Anti-atherosclerotic effect of incretin mimetics: a meta-analysis of randomized controlled trials
por: Barbarawi, Mahmoud, et al.
Publicado: (2018)

GLP-1R signaling neighborhoods associate with the susceptibility to adverse drug reactions of incretin mimetics
por: Wright, Shane C., et al.
Publicado: (2023)

Neuroprotective Effects and Treatment Potential of Incretin Mimetics in a Murine Model of Mild Traumatic Brain Injury
por: Bader, Miaad, et al.
Publicado: (2020)

Thrombospondin-1 mimetics are promising novel therapeutics for MYC-associated medulloblastoma
por: Chan, Tiffany S Y, et al.
Publicado: (2021)

How should we think about the unprecedented weight loss efficacy of incretin-mimetic drugs?
por: Gou, Yang, et al.
Publicado: (2023)

Gene Therapy for Spinal Muscular Atrophy: An Emerging Treatment Option for a Devastating Disease
por: Rao, Vamshi K., et al.
Publicado: (2018)

Incretin-Based Therapies for the Treatment of Type 2 Diabetes: Evaluation of the Risks and Benefits
por: Drucker, Daniel J., et al.
Publicado: (2010)

Prevalence of Incretin-Mimetic and Sodium-Glucose-Transporter-2-Inhibitor Therapy in German Hospitalized Type-2 Diabetics Following Myocardial Revascularization: An Observational Study
por: Pliquett, Rainer U., et al.
Publicado: (2020)

Comparison of incretin immunoassays with or without plasma extraction: Incretin secretion in Japanese patients with type 2 diabetes
por: Yabe, Daisuke, et al.
Publicado: (2011)

Updates of incretin‐related drugs for the treatment of type 2 diabetes
por: Araki, Hirotaka, et al.
Publicado: (2022)

The burden of sialorrhoea in chronic neurological conditions: current treatment options and the role of incobotulinumtoxinA (Xeomin®)
por: Morgante, Francesca, et al.
Publicado: (2019)

Intramuscular Interferon Beta-1a and Evolving Treatment Options and Outcomes Measurement for MS: Considerations for Managed Care
por: Barnes, Christopher J., et al.
Publicado: (2013)

Digital health promotion: promise and peril
por: Koh, Amanda, et al.
Publicado: (2021)

Incretins and cardiovascular disease: to the heart of type 2 diabetes?
por: Solini, Anna, et al.
Publicado: (2023)

Innovating With Rehabilitation Technology in the Real World: Promises, Potentials, and Perspectives
por: Chua, Karen Sui Geok, et al.
Publicado: (2017)

New Therapeutic Paradigms and Guidelines in the Management of Pulmonary Arterial Hypertension
por: Hill, Nicholas S., et al.
Publicado: (2016)

Incretin Hormones: Pathophysiological Risk Factors and Potential Targets for Type 2 Diabetes
por: Rosenberg, Jared, et al.
Publicado: (2021)

Managing Type 2 Diabetes: Going Beyond Glycemic Control
por: Stolar, Mark W., et al.
Publicado: (2008)

Burden of Illness in Type 2 Diabetes Mellitus
por: Cannon, Anthony, et al.
Publicado: (2018)

Potential therapeutic implications of new insights into respiratory syncytial virus disease
por: Openshaw, Peter JM
Publicado: (2002)

Current State of Clostridium difficile Treatment Options
por: Venugopal, Anilrudh A., et al.
Publicado: (2012)

Incorporating health equity into value assessment: frameworks, promising alternatives, and future directions
por: Diaby, Vakaramoko, et al.
Publicado: (2021)

Type 2 Diabetes and Cardiovascular Disease: Reducing the Risk
por: Bartels, David W., et al.
Publicado: (2007)

Incretin Action in the Pancreas: Potential Promise, Possible Perils, and Pathological Pitfalls
por: Drucker, Daniel J.
Publicado: (2013)

The evolving place of incretin-based therapies in type 2 diabetes
por: Gallwitz, Baptist
Publicado: (2010)

Incretin response in Asian type 2 diabetes: Are Indians different?
por: Singh, Awadhesh Kumar
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_v9d8jav1nsg4q3db2ca7jsdet1